Study Stopped
Withdrawn in October 2006, no longer of interest
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2006
CompletedFirst Posted
Study publicly available on registry
February 17, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2006
CompletedMay 23, 2013
May 1, 2013
February 15, 2006
May 22, 2013
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Metastatic or unresectable clear cell renal cell carcinoma
- Measurable disease
You may not qualify if:
- Prior interferon therapy
- More than 3 prior therapy regimens
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Olencki
Ohio State University
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 15, 2006
First Posted
February 17, 2006
Study Completion
November 1, 2006
Last Updated
May 23, 2013
Record last verified: 2013-05